NCT06277752View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

March 16, 2024

Study Completion Date

March 16, 2024

Conditions

Gout Arthritis

Interventions

DRUG

dose-5 group

IBI128 300mg po. QD(Quaque Die)

DRUG

dose-1 group

IBI128 25mg po. QD(Quaque Die)

DRUG

dose-2 group

IBI128 50mg po. QD(Quaque Die)

DRUG

dose-4 group

IBI128 200mg po. QD(Quaque Die)

DRUG

dose-3 group

IBI128 100mg po. QD(Quaque Die)

Trial Locations (1)

450000

The First Affiliated, Zhengzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06277752 - A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) | Biotech Hunter | Biotech Hunter